Helicobacter pylori infection is the major cause of gastric cancer, and removal of H. pylori infection from a population could theoretically decrease the number of cases by about 89%. However, in real-life settings, few studies have reported the effect of screening and treating this pathogen in population-based programs. This is mainly because of the lack of an adequate infrastructure for delivery of systematic screening services to asymptomatic individuals, the lack of standardization to ensure that each subject receives the correct diagnostic testing and antibiotic treatment, and limited resources. We illustrate our method of implementing two population-based screen-and-treat programs in Taiwan, where the epidemiological characteristics of disease burden have changed from the traditionally Eastern pattern towards that of the Western countries. Our first example is a high-risk population that resides on an offshore island, in which a strategy of mass eradication of H. pylori was applied. The other example is an intermediate-risk population, which is representative of the general average-risk population, in which there is integration of the screen-and-treat method with the established framework of colorectal cancer screening using the fecal-occult blood test. The information provided here may be useful for integration of gastric cancer prevention measures into the healthcare priorities of populations with different gastric cancer risks, such as those with limited resources.
Introduction
Gastric carcinogenesis is a multifactorial process, in that there are interactions among the host, environment, and microbiome. 1 Several methods can decrease the burden of gastric cancer, including endoscopic screening (secondary prevention) and chemoprevention (primary prevention). The chemopreventive agents include antibiotic treatment for Helicobacter pylori infection, vitamins, minerals, and antioxidants, such as α-tocopherol, β-carotene, vitamin C, selenium, curcumin, and green tea. 2 Among these many preventive measures, eradication of H. pylori infection is the most effective method to prevent gastric cancer. 3 Even though H. pylori eradication is currently a common practice at the individual level, active screening and treating H. pylori infection at the population level is rare. 4 This demonstrates a significant gap in the translation of findings from small-scale clinical trials into large population-based screening programs. The decision to institute a mass eradication program is clearly a complex issue, because it is necessary to consider topics such as disease prevalence, the infrastructure for delivery of screening services, cost-benefit analysis, and allocation of scarce resources, all of which are important. Populations in eastern Asia have the highest gastric cancer burden in the world, and this region accounts for more than 60% of all gastric cancer cases worldwide. 5 Thus, this region is especially well suited for implementing a preventive strategy. For example, the age-standardized rates of gastric cancer in Korea, Mongolia, Japan, and China are estimated as 41.8, 32.5, 29.9, and 22.7 per 100 000 person years, respectively. There is a trend of declining incidence of gastric cancer in East Asia, because sanitation doi:10.1111/jgh. 13726 and hygiene have improved in recent years and because searching for H. pylori infection and providing curative treatment is now a standard method for management of peptic ulcer disease and dyspepsia symptoms. However, the disease burden remains significant due to the increasing numbers of elderly individuals, who have been exposed to risk factors for many decades. For example, in 1997, the government of Taiwan approved the indication of H. pylori eradication in cases with peptic ulcer disease. This policy led to declining incidence rates for gastric cancer in three age groups from 1999 to 2013 (30-49 years old: 6.5 to 5.4 per 100 000 person years; 50-69 years old: 34.7 to 27.2 per 100 000 person years; 70-85-+ years old: 132.6 to 116.1 per 100 000 person years). However, the absolute numbers of new cases of gastric cancer were 3459 in 1999-2003, 3647 in 2004-2008 , and 3855 in 2009-2013, indicating the effect of population aging. 6 On the global scale, the International Agency for Research on Cancer also estimates that the crude incidence rate of gastric cancer will remain stable or even increase by 2030 due to an increase in the elderly population and the lack of effective preventive measures. 3 Under these circumstances, we expect the incidence of gastric cancer in the Asia-Pacific region to gradually decline (following what happened in Western countries), although such a trend likely may only occur after several decades. Efforts to accelerate the declining incidence of gastric cancer, which is already in progress, and to integrate gastric cancer prevention with other pressing issues are key for implementation of a mass eradication program.
This article is mainly based on presentations at two consecutive conferences of the Asia-Pacific Digestive Week. The first one, entitled "Chemoprevention of Gastric Cancer by Helicobacter pylori Eradication and Long-term Use of NSAIDs and Aspirin," was presented in the Marshall & Warren Lectureship in 2015 (Taipei, Taiwan), and the second one, entitled "Gastric Cancer Prevention Trials in Taiwan," was presented in Gastric Cancer Prevention Guideline Consensus Symposium in 2016 (Kobe, Japan). These two presentations summarize the ongoing work on prevention of gastric cancer over the past two decades in Taiwan and demonstrate how we implemented a population-based screen-and-treat program for H. pylori infection. These efforts included search for funding and administrative support from the local government, integrating the control of other emerging disease entities due to the Westernization of lifestyles in Taiwan and providing the population with systematic and organized screening services.
What is the benefit of H. pylori eradication on reducing the risk of gastric cancer?. It is necessary to understand the magnitude of the benefit of a mass H. pylori eradication program before proposing such a program to the stakeholders and policy-makers who provide funding support. After H. pylori infection, virtually, all cases develop chronic active gastritis, and some progress to atrophic gastritis, intestinal metaplasia, dysplasia, and eventually gastric cancer, following Correa's cascade (Fig. 1) . 7 In this multistage process, H. pylori infection, 8 tobacco smoking, 9 excessive alcohol use, 10 excessive salt intake, 11 consumption of preserved foods containing nitrosamine, 12 and genetic factors 13 are associated with the more rapid progression. Most of these risk factors can be eliminated with improvements in diet (fruit and vegetable consumption) and social habits. H. pylori infection, by contrast, tends to be lifelong without active treatment. Hence, H. pylori infection is the major risk factor, and the benefit from its removal can be quantified. Previous research showed that H. pylori carriers have a pooled odds ratio (OR) of about 6 for developing gastric cancer, and removal of H. pylori from a population can reduce the burden of gastric cancers by 89% (non-cardiac gastric cancer), 29% (cardiac gastric cancer), and 74% (gastric non-Hodgkin lymphoma). 14, 15 When screening an entire population, however, we must consider that the population has subjects of different ages and different levels of risk. Some subjects may receive screening when their intra-gastric histology has progressed into an intermediate stage (e.g. chronic active gastritis and atrophic gastritis); eradication therapy is effective in arresting the progression and can even lead to regression of these mucosal changes in these individuals (Fig. 2, subjects 1 and 3) . Some subjects may have developed gastric cancer at the time of, or just before, screening (subjects 2 and 5); endoscopic examination is needed for these individuals. The majority of H. pylori carriers may only have minimal inflammatory changes in their gastric mucosa (subject 4); even without eradication therapy, the gastritis may progress slowly, in which case they have a very low risk of gastric cancer. Theoretically, if H. pylori infection is eliminated at an early age, for example, when individuals are healthy or only have mild gastritis, then about 89% of non-cardiac gastric cancers can be eliminated. 14, 15 However, in reality, subjects undergo screening at diverse ages, so institution of mass screening and eradication may decrease the risk of gastric cancer but cannot completely eliminate it. Vaccination may be more effective, although the available evidence is limited regarding the long-term efficacy and the generalizability to other populations. 16 Evidence from randomized controlled trials and cohort studies. A recent meta-analysis 17 summarized 24 studies from China, Colombia, Finland, Japan, Korea, and Taiwan to evaluate the benefit of H. pylori eradication on gastric cancer. There were 715 incident gastric cancers among 48 064 individuals and 340 255 person years of follow-up. Fourteen of these studies examined asymptomatic infected individuals (primary prevention), [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] and 10 examined individuals who received endoscopic resection of early gastric cancers (tertiary prevention) [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] (Table 1) . The meta-analysis showed that eradication of H. pylori infection was associated with a 47% reduction in risk of gastric cancer, and there was no significant heterogeneity among studies.
Further inspection of the data showed that the baseline gastric cancer incidence (i.e. incidence rate of gastric cancer in the control group) in these studies ranged from 34.3 to 10 256.4 per 100 000 person years, reflecting a large range of gastric cancer risk among the study populations. However, analysis of the incidence rate ratio as a function of the baseline incidence rate (Fig. 3) , indicated that H. pylori eradication provided a significant benefit, in that the incidence rate ratio of gastric cancer decreased with increasing baseline incidence rate. These results indicate that studies of high-risk individuals have superior statistical power to demonstrate a benefit, but assessment of the benefit for low-to-intermediate risk groups are constrained by insufficient sample size and short follow-up period. Therefore, there should be active screening and treatment for H. pylori infection to prevent gastric cancer in high-risk populations, for whom significant benefits occur after a relatively short followup period. Such subpopulations actually exist in most countries and include subjects with strong family histories of gastric cancer, subjects with atrophic gastritis, intestinal metaplasia, and/or dysplasia, subjects with a low serum pepsinogen (PG) levels, and patients who underwent endoscopic or surgical resection of gastric neoplasia.
Recommendations from international consensus meetings. Several consensus meetings have emphasized the importance of applying the strategy described previously at the population level to decrease the burden from gastric cancer. Starting in 2008, the Asia-Pacific Consensus Guidelines on Gastric Cancer Prevention 42 stated
There is a pressing need for the development of national policies to reduce the incidence of gastric cancer which is now feasible; H. pylori screen and treat is a gastric cancer risk reduction strategy in high-risk populations; and in a high-risk population, screening for H. pylori infection is most effective before atrophic gastritis has developed. Focusing on the onset of the pathogenesis of gastric cancer, the 2015 Kyoto global consensus report on Helicobacter pylori gastritis 43 stated
Depending on the epidemiological context, it is appropriate to search and screen for H. pylori gastritis at an age before development of atrophic gastritis and intestinal metaplasia; and H. pylori infected individuals should be offered eradication therapy, unless there are competing considerations.
The recently published Maastricht V/Florence Consensus Report 44 provided further recommendations on how to implement this strategy:
H. pylori eradication for gastric cancer prevention is cost-effective in communities with a high risk for gastric cancer; H. pylori eradication offers clinical and economic benefits other than gastric cancer prevention and should be considered in all communities; H. pylori 'screen-and-treat' strategies are recommended in communities at high risk of gastric cancer; and screenand-treat for H. pylori is recommended in individuals at increased risk for gastric cancer.
The International Agency for Research on Cancer also indicated the urgent need for effective preventive measures and for a critical assessment of H. pylori eradication as a preventive strategy. 
Screening and treating H. pylori infection at the population level: experiences from Taiwan
In Taiwan, organized gastric cancer prevention began in 1995 for a high-risk population (n = 5000 for subjects aged 30 or more) who lived on Matsu Islands, where the incidence rate of gastric cancer is about 100 per 100 000 person years. Based on the favorable results of this cohort study (more than 2 decades of follow-up), the results were disseminated to other healthcare authorities in Taiwan. Starting in 2012, a preventive program, using a modified screening design and eligibility criteria, was implemented in a general population in Changhua County (western Taiwan). This program focused on a population with intermediate gastric-cancer risk (incidence rate about 16 per 100 000 person years) and integrated the mass eradication of H. pylori with colorectal cancer screening. Since then, the staged implementation of this policy was extended to other counties and cities. We describe the methods used for screening, evaluation, and future perspectives, of these two population-based programs below. 45, 46 An effective prevention strategy was urgently needed for this high-risk population.
Matsu Islands Gastric Cancer Prevention
Between 1995 and 1998, a population-based screening program for gastric cancer prevention, based on a two-staged design, was conducted in the Matsu Islands. The first stage consisted of measurement of anti-H. pylori immunoglobin G antibodies and serum PG; for those who tested positive, an upper endoscopy was administered at the second stage in an effort to detect gastric cancer at the preclinical phase. However, the positivity rate of this screening approach was rather high, and the number of subjects who received subsequent endoscopy was low, so the cancer detection rate was unsatisfactory. Thus, this program ended in 1999.
Starting in 1999, a multiple-disease screening program was launched that screened for several prevalent diseases in this population, including non-neoplastic diseases (diabetes mellitus, hypertension, and hyperlipidaemia) and neoplastic diseases (cervical, breast, and colorectal cancers). 47 The potential participants were contacted by telephone, and they received pamphlets by mail that invited them to visit a local screening unit. This program provided an opportunity to implement a screen-and-treat procedure for H. pylori infection, because the needs for additional manpower and infrastructure were minimal. Starting in 2004, mass screening for H. pylori with C 13 -urea breath testing was incorporated into this multiple-disease screening program. 44 The main outcome measures were changes in intra-gastric histology, incidence of premalignant gastric lesions, and gastric cancer incidence.
In 2008, after 5 years of follow-up, the H. pylori infection declined by 78.7%, atrophic gastritis declined by 77.2%, and peptic ulcer declined by 67.4%. 30 These promising findings (although they are surrogate outcome measures for gastric cancer) further motivated the community to participate in the screening program and served as a strong basis for obtaining continued funding from the local government.
Up to now, there were five rounds of mass eradication (2004, 2008, 2012, 2014, and 2016) , and the H. pylori infection rate in this population steadily declined from 63% at 2004 to below 10% in 2016; the reinfection rate declined as well. We estimated the reduction of gastric cancer as 25% in 2008 and 47% in 2015, assuming the annual incidence rate continued to decline at the same rate. These predictions will be verified in 2018, when the statistics of National Cancer Registry are available. Computer simulations indicated that early H. pylori eradication once in lifetime is more cost-effective than the traditional approach of using biomarkers and then endoscopy. 48 In addition to achieving the main purpose of gastric cancer prevention, several other outcomes from this program deserve discussion. First, killing of antibiotic-susceptible strains may lead to the proliferation of resistant strains. 49 This may be especially true when multi-drug combinations are used, which is increasingly common, but dangerous because it unnecessarily exposes susceptible strains to an additional antibiotic. This problem may relate not only to the emergence of H. pylori that will become increasingly difficult to treat, but also to the development of antibiotic resistance in other bacterial flora of the gastrointestinal tract from the exposure of multiple antibiotics during anti-H. pylori treatment. However, evidence regarding the effect of a relatively short-course of anti-H. pylori treatment on antibiotic resistance is limited. In this program, the H. pylori antibiotic resistant pattern was investigated during 2012-2014, after two rounds of mass eradication. The results showed that the percentage of H. pylori strains resistant to clarithromycin, metronidazole, amoxicillin, Figure 3 Relationship of the incidence rate ratio of gastric cancer with baseline gastric cancer incidence (log scale). Circles indicate incidence rate ratios in individual studies; size of bubble is proportional to precision (inverse of variance) of incidence rate ratio. This benefit is statistically significant when the baseline gastric cancer incidence exceeds 150 per 100 000 person years; the incidence rate ratio continues to decrease with rising baseline incidence up to about 1200 per 100 000 person years, and then stabilize. Adapted from Lee et 
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and levofloxacin were 7.6%, 22.7%, 0.7%, and 3.9%, respectively. 50 This is lower than the resistance rates from a hospitalbased study in Taiwan during the same period (11.5%, 28.6%, 1.3%, and 14.7%, respectively) and suggests that the routine retest-and-retreat practice limits the development of antibioticresistant strains.
It also remains unclear whether the mass eradication of H. pylori selects for antibiotic-resistance in other species of bacteria. In two studies, fecal samples were obtained from patients and controls before and after treatment, and researchers found that triple therapy could lead to persistent antibiotic resistance in the normal microbiota. 51, 52 Whether a short course of H. pylori eradication can permanently select other antibiotic-resistant bacterial flora remains to be clarified using large-scale studies.
Second, the optimal regimen for treating the asymptomatic population remains unclear. Most studies that evaluated the efficacy of H. pylori eradication focused on symptomatic subjects who were recruited from hospitals. In these studies, researchers tended to increase the duration of treatment and the number of antibiotics to increase the eradication rate. Asymptomatic carriers may be less likely to tolerate long and complex antimicrobial regimens. This is supported by our comparison between the community-based and the hospital-based studies in Taiwan. 50 We found lower eradication rates from triple therapy for 14 days and sequential therapy for 10 days in the community population, even though they had a lower prevalence rate of antibiotic resistance strains. This observation can be explained by the lower compliance of the community population to the prescribed antibiotic treatment.
Third, H. pylori infection is associated (positively or negatively) with several extra-gastric diseases, such as gastroesophageal reflux, childhood asthma, atopy, and cardiovascular disease. Nonetheless, the existence of confounding variables in studies reporting these relationships makes it difficult to establish causeand-effect relationships. In the Matsu Islands population, we found an increased prevalence of endoscopic esophagitis following mass eradication. 30 This may be because of the high prevalence rate of atrophic gastritis in this population (about 60%) before implementation of the eradication program. When we re-evaluated the intragastric histology in 2008, there were significant improvements in atrophic mucosa, and the prevalence rate of atrophic gastritis declined to about 14%. This observation indicates that impaired acid production was restored following H. pylori eradication, through reversal of atrophic gastritis. The increased prevalence of endoscopic esophagitis was not clinically relevant in this population. Up to now, there were no cases of esophageal adenocarcinoma in this population, and most cases of endoscopic esophagitis were low grade, with most subjects having no symptoms of reflux. Furthermore, we cannot exclude the roles of other factors, such as the increases in age and obesity that occurred over time in this population. Undoubtedly, the burden of gastric cancer outweighs this possible danger, especially when considering the long time it takes for reflux esophagitis to undergo malignant transformation. 53 Changhua County Gastric Cancer Prevention Program. In Taiwan, the H. pylori infection rate and gastric cancer incidence are greater in rural areas, such as the Matsu Islands. Changhua County, in central Taiwan, has a population of about 1 300 000. For individuals aged 50-69 years, the annual gastric cancer incidence rate was about 29 per 100 000 person years, and the mortality rate was about 15 per 100 000 person years during 2013, near the median of all Taiwanese counties and cities. Because of the increasing trend of colorectal cancer in Taiwan, the government has initiated a mass screening program for colorectal cancer using biennial fecal occult-blood tests for adults who are 50-69 years of age. [54] [55] [56] This established delivery system could be readily adapted into a two-in-one test: a stool sample test panel for colorectal cancer (with fecal immunochemical test [FIT] ) and gastric cancer prevention (with H. pylori stool antigen test [HPSA] ). In fact, such a pilot program was launched in Changhua County in 2012. 57 Those who tested positive for the FIT and HPSA were referred for colonoscopic confirmation and antibiotic treatment, respectively.
After a 2-year feasibility study, a population-based randomized controlled trial (trial registration number: NCT01741363) was launched in 2014 under the auspices of the Health Promotion Administration, Ministry of Health and Welfare. This trial plans to enroll 30 000 subjects in a case arm (FIT + HPSA) and 30 000 in a control arm (FIT alone) during the 4-year enrollment period. After completion of subject enrollment, the outcome of participants will be traced for 5 to 10 years by searching the database of the National Cancer Registry.
In this large-scale community-based trial, in which the target population is representative of the general average-risk population in Taiwan, it is mandatory to offer all participants the opportunity to receive equal quality of treatment and follow-up. To reach this goal, nationwide consensus statements were developed in 2016 under the auspices of the Gastroenterological Society of Taiwan and the Ministry of Health and Welfare. These included three major sections: (i) optimal diagnosis and indications; (ii) current treatment strategies; and (iii) screening-to-treat and surveillance for control of gastric cancer. These consensus statements can serve as a reference for physicians to standardize their management of H. pylori infections, especially in areas with high prevalence of H. pylori infection and gastric cancer. 58 After H. pylori eradication, what can be recommendedforgastriccancerprevention?. In both screening programs, the mean age of participants was about 50-60 years old, similar to most previous chemoprevention trials. Therefore, we expect that H. pylori eradication may reduce the risk of gastric cancer by about 50%, not the theoretically expected 89% that is estimated from the prevalence of cancer cases with H. pylori infection (i.e. the population attributable fraction). 14, 15 This is supported by our observations on the Matsu Islands that some subjects who experienced successful eradication nonetheless developed gastric cancer after 10 years of follow-up. Several serological and histological methods can identify subjects who remain at risk for gastric cancer. Figure 4 summarizes these methods in an algorithm that integrates the first stage of screen-and-treat of H. pylori infection, with the second stage of risk stratification according to the serological and histological results, to effectively allocate the limited resources available for endoscopic surveillance.
Risk stratification for endoscopic surveillance after H. pylori eradication. Serological test for PG I and II, which can indicate the loss of functional gastric glands and the presence of hypoacidity, is one option to select at-risk subjects and limit the number of endoscopic examinations. Thus, in the Matsu Islands Gastric Cancer Program, a serological screening program was launched in 2015 and added to the mass eradication program. This population experienced multiple rounds of mass eradication, and the atrophic mucosa of treated patients may regenerate after eradication. Thus, we expected the positivity rates of PG I and II to be lower than from 1995 to 1998 (before the mass eradication program). Preliminary results showed that the positivity rates of PG I and II were only about 3-4% in this population; among those who tested positive, atrophic gastritis and gastric cancer were more common.
Second, use of histological grading systems that consider the severity and extent of gastritis, such as the updated Sydney system, the Operative Link for Gastritis Assessment, and the Operative Link on Gastric Intestinal Metaplasia Assessment staging systems, is another option. For these systems, biopsy samples are taken at different gastric subsites (both antral and corpus mucosa). The distribution of inflammation, atrophic mucosa, and intestinal metaplasia is associated with the risk of peptic ulcer and gastric cancer, and the results help to determine the need for endoscopic surveillance. 43 However, the PG test is mainly effective in identifying gastric cancers that follow Correa's cascade (i.e. intestinal-type gastric cancer pathway) and may have limited value in detection of gastric cancers that develop directly from non-atrophic gastritis (i.e. diffuse-type gastric cancer pathway). 59 The PG test has a positive likelihood ratio of about 6 in prediction of atrophic gastritis, 60 so these results should be highly correlated with those from histological results. 61 Therefore, each individual method seems ill-suited to cover the full spectrum of gastric cancer subtypes.
To resolve this limitation, recent research has focused on molecular methods of detection. For example, recent studies showed that accumulation of aberrant DNA methylation in noncancerous mucosae can produce field cancerization, so measurement of epigenetic alterations in the gastric mucosa after eradication may be a promising approach. 62 Asada et al. found that measurement of the methylation of miR-124a-3, EMX1, and NKX6-1 was useful in predicting the risk of metachronous gastric cancer after endoscopic resection of early gastric cancer. 63 In addition to serological and histological assessments, certain demographic factors can also be useful for risk stratification. Based on the National Health Insurance Research Database of Taiwan, researchers found that H. pylori eradication, age, sex, peptic ulcer sites, peptic ulcer complications, nonsteroidal antiinflammatory drug (NSAID) use, and surveillance endoscopy were significantly associated (either positively or negatively) with the risk of gastric cancer. A resulting nomogram, based on each patient's risk score for each predictor, can estimate an risk of gastric cancer within a 2-year period. 64 Additional chemopreventive methods. Many casecontrol and cohort studies showed that excessive salt intake and use of tobacco and alcohol are associated with increased risk of gastric cancer, but that consumption of fresh fruits and vegetables reduces this risk. Instructions regarding lifestyle changes are necessary following H. pylori eradication, although sustained lifestyle modification is difficult, and the magnitude of benefit is hard to quantify.
For subjects who already have extensive atrophic gastritis, intestinal metaplasia, or low-grade dysplasia, some studies indicated that long-term use of NSAIDs and aspirin may reduce the risk of gastric cancer. Ristimaki and colleagues reported overexpression of cyclooxygenase-2 (COX-2) in human gastric carcinoma tissue. 65 An in vitro study of our research group found H. pylori infection induced COX-2 expression through activation of NF-kB, NF-interleukin 6, and the cAMP response element, implicating a role of COX-2 overexpression in gastric carcinogenesis. 66 Another of our studies reported that H. pylori upregulation Helicobacter pylori and gastric cancer Y-C Lee and J-T Lin of COX-expression enhanced cancer cell invasion and angiogenesis via TLR2 and TLR9, and that specific COX-2 inhibitors, NS398 or celecoxib, attenuated this effect. 67 A clinical study showed COX-2 expression correlated positively with the presence of atrophic gastritis and intestinal metaplasia among H. pylori-infected relatives of gastric cancer patients; after H. pylori eradication, gastric COX-2 expression was undetectable, especially in relatives without intestinal metaplasia. 68 Collectively, these studies suggest that COX-2 may play a crucial role in H. pylori-related gastric cancer, and that COX-2 inhibition may provide chemopreventive effects.
Wang et al. conducted a meta-analysis of 2831 gastric cancer cases from eight case-control and one cohort studies. They found that NSAID use significantly reduced the risk of gastric cancer, with a summary OR of 0.78. Users of aspirin (OR: 0.73) and non-aspirin NSAIDs (OR: 0.74) experienced similar benefits. Furthermore, the benefit appeared to be dose-dependent. 69 A multiethnic cohort study found that regular use of aspirin decreased the risk of noncardiac gastric cancer, with a hazard ratio (HR) of 0.73, but use of non-aspirin NSAIDs had no such effect. The protective effect of regular aspirin use only occurred for intestinal-type distal gastric cancer (HR: 0.66), not for diffuse-type gastric cancer. 70 Another cohort study reported use of any dose of aspirin (HR: 0.64) or NSAIDs (HR: 0.68) significantly reduced the risk of non-cardiac gastric cancer. However, use of aspirin or other NSAIDs was not significantly associated with cardiac gastric cancer. 71 Our research group used the Taiwan National Health Insurance Research Database and found that patients with peptic ulcers who never used NSAIDs had a higher risk of gastric cancer than those in the general population, and that regular NSAID use reduced the risk. Multivariate analyses showed that regular NSAID use provided significant protection from gastric cancer (HR: 0.79 for each year), especially in patients with H. pylori-associated cancer (HR: 0.52 for each year). 72 However, other studies reported no effects or negative effects of aspirin and NSAIDs. For example, Cook et al. reported no preventive effect of aspirin for any cancer, including gastric cancer. 73 They also found that use of aspirin and NSAIDs had significant adverse effects, such as the bleeding complications, especially in the elderly. A systematic review of 17 epidemiological studies reported an increased relative risk (RR) of upper gastrointestinal tract bleeding associated with aspirin use in cohort studies and nested case-control studies (RR: 2.2), and in non-nested case-control studies (RR: 3.1). 74 Other studies examined the use of selective COX-2 inhibitors, which have a reduced ulcerogenic effect. Yanaoka et al. evaluated the effect of etodolac on the risk of metachronous cancer after endoscopic resection of early gastric cancer. 75 They found that long-term treatment did not influence the extent of metaplastic gastritis, as indicated by endoscopic findings, but it did reduce development of metachronous cancer in patients with extensive metaplastic gastritis. Wong et al. enrolled 1024 participants with H. pylori infection and advanced gastric lesions in a randomized trial. They randomly assigned participants into four groups, using a two-by-two factorial design: placebo alone; anti-H. pylori therapy (7 days) + placebo (24 months); placebo (7 days) + celecoxib (24 months); and anti-H. pylori therapy (7 days) + celecoxib (24 months). 76 Analysis of precancerous lesions indicated significant regression in the two groups given celecoxib (OR: 1.72) and in the two groups given anti-H. pylori treatment (OR: 2.19). However, the effect was not significant for cases receiving H. pylori eradication followed by celecoxib. They also reported no severe adverse events during the 2-year follow-up period. However, gastric cancer developed in one subject (0.4%) in the placebo group, three (1.4%) in the anti-H. pylori + celecoxib group, three (1.3%) in the anti-H. pylori + placebo group, and two (0.9%) in the celecoxib COX-2 inhibitor group; these differences were not statistically significant.
Based on these observations, chemoprevention using NSAID/aspirin after H. pylori eradication may be useful for prevention of subsequent carcinogenesis. However, support for this recommendation from large-scale randomized trials is limited, and this treatment may lead to adverse effects, such as gastrointestinal bleeding. Hence, clinicians must carefully consider the benefits and harms of this chemopreventive treatment.
Conclusions
In conclusion, we are now confident that chemoprevention of gastric cancer can be achieved through a short-course antibiotic treatment that eradicates H. pylori. At the population level, mass screening and treatment of H. pylori infection can be achieved by integration with other healthcare strategies currently used for populations with intermediate or high risk of gastric cancer. Following mass eradication of H. pylori, some subjects still have an increased risk of gastric cancer. These individuals may benefit from endoscopic surveillance using risk-stratification methods based on the serological, histological, and molecular approaches. Although some studies suggested that use of NSAIDs/aspirin may provide a chemopreventive effect, by halting the progression of precancerous lesions, the bleeding risk from long-term use of these drugs should be carefully considered before administration in clinical practice.
